Founded in 2011, Neurexpert is at the forefront of neuroscience-driven drug discovery. We specialize in cutting-edge assays that deliver high-quality data on compound potency and efficacy—directly at the native target. Our unique approach bridges the crucial gap between traditional in vitro screens and complex in vivo models, confirming mechanisms of action and uncovering the neural pathways that drive higher brain functions like cognition and sensory processing. Whether you're in the early stages of target validation or advancing toward clinical development, our expertise supports every step of your journey. From screening to functional biomarker studies, Neurexpert provides the critical insights needed to accelerate progress and de-risk your pipeline.
Stuart Neale, PhD, Chief Executive Officer, is a seasoned electrophysiologist and neuroscientist with over 20 years of experience at the forefront of pharmaceutical, academic, and clinical research. His expertise lies in developing innovative electrophysiology assays that drive drug discovery efforts, from start-ups to large pharmaceutical companies.
With a proven track record of success, Stuart has seamlessly integrated electrophysiology insights into multidisciplinary project teams, accelerating drug discovery and early development across a wide spectrum of nervous system disorders.
Under his leadership, Neurexpert continues to push the boundaries of neuroscience research, delivering actionable solutions for complex challenges in the field.
Tom Salt, PhD is a Fellow of the British Pharmacological Society, Emeritus Professor at University College London (UCL), and Honorary Professor at Newcastle University's Institute of Neuroscience, our Chief Scientific Officer brings unparalleled expertise to Neurexpert.
His groundbreaking research spans neurotransmitter pharmacology in the visual and somatosensory/pain systems, as well as the functional impacts of retinal degeneration in eye diseases. With over 200 publications in prestigious journals like Nature, Science, Nature Neuroscience, and PNAS, he is a recognized leader in the field and serves on several editorial boards.
In addition to his academic achievements, he has contributed significantly to the pharmaceutical industry, providing consultancy and advisory services to drive innovation and discovery.
